

IMDRF /DITTA joint workshop on

Artificial Intelligence in Healthcare
Opportunities and Challenges

Monday 16 September 2019

Venue: Hyatt Regency, 8, Ulitsa Borisa Yel'tsina, St, Yekaterinburg

Artificial Intelligence (AI) in Healthcare is receiving more and more attention. For example, healthcare providers are embedding the technology into their workflows and the decision-making processes. AI is aimed at improving outcomes for patients and other healthcare stakeholders. Uncertainty about regulatory appreciation of AI in Healthcare is leading to a variety of national legislative initiatives, risking serious fragmentation and limitation of exploiting what AI has to offer. We will only get the full benefits of Artificial Intelligence in Healthcare if we appropriately identify and address the key regulatory challenges which will be discussed during the workshop.

This workshop provides a unique opportunity to gain a status overview of regulatory and standardization initiatives across the world and to openly discuss possibilities to converge on future regulatory obligations. Still AI is not something to automatically regulate, thus participants will discuss what is applicable, how to apply, or whether we need to adapt existing regulatory frameworks and IMDRF guidance documents. This event will also include a discussion on possibilities of global convergence in the IMDRF context.

Morning moderators: Vladimir Kutichev, Head of medical device software lab, Roszdravnadzor, Russia; Aysylu Valeeva, Deputy Head of Division of organization of state control and registration of medical devices, Roszdravnadzor, Russia

Afternoon moderator: Peter Linders, Philips

DRAFT AGENDA *

* The IMDRF Secretariat reserves the rights to make changes to the workshop program

| No | Topic | Speaker | Scheduled Time |
|---|---|---|----------------|
| Welcome coffee and registration | | | 8:30 – 9:00 |
| Section 1: Opening Remarks | | | |
| 1a | Welcome from IMDRF Chair | Elena Astapenko, Head of Division of organization of state control and registration of medical devices, Roszdravnadzor, Russia | 9:00 – 9:10 |
| 1b | Welcome from DITTA | Nicole Denjoy, DITTA Chair | 9:10 – 09:20 |
| Section 2: AI in Healthcare and regulatory developments (industry and healthcare professionals view) | | | |
| <ul style="list-style-type: none"> • Introduction into AI; • Concrete examples by industry of AI software in different application areas; • What does AI bring to healthcare from a clinician's perspective; • Development of AI based software causes both new opportunities as well as new challenges | | | |
| 2a | Introduction into AI and its unique characteristics | Robert Phillips, Siemens Healthineers | 9:20 – 9:35 |

| | | | |
|--|---|--|---------------|
| 2b | What does AI bring to healthcare and AI examples including application in Oncology | Olga Bakhvalova, Philips, Russia | 9:35 – 9:50 |
| 2c | Prospects for the use of artificial intelligence technologies in the Russian healthcare system | Alexander Gusev, Expert at K-MIS, Member of the Expert Council of the Ministry of Health of the Russian Federation on the use of information and communication technologies in the healthcare system | 9:50 – 10:05 |
| 2d | Creating an Artificial Intelligence Market for Health service | Andrey Almazov, Member of the supervisory board of the association of developers and users of artificial intelligence in medicine "National Medical Knowledge Base", Russia | 10:05 - 10:20 |
| 2e | The participation of the Skolkovo Foundation in the development of medical artificial intelligence in Russia. Features of the launch of a Russia-based startup on the global market | Vladimir Egorov, Skolkovo Foundation, Senior Project Manager, Biological and medical technology cluster, Russia | 10:20 – 10:35 |
| 2f | Panel discussion | Panelists | 10:35 - 10:55 |
| Coffee/tee break | | | 10:55 - 11:15 |
| Section 3: AI in Healthcare and regulatory developments: possibility and challenges (regulatory view) | | | |
| • Current regulatory practice and Overview of regulatory developments on AI | | | |
| 3a | Perspectives and Regulatory Considerations for AI and Big Data in Medical Devices | Seungho Son, Ministry of food and drug safety (MFDS), South Korea | 11:15 - 11:30 |
| 3b | WHO view for AI | Adriana Velasquez, Senior Advisor of medical devices, World Health Organisation | 11:30 – 11:45 |
| 3c | Regulatory framework on medical devices using AI technology in Russia | Vladimir Kutichev, Head of medical device software lab, Roszdravnadzor, Russia | 12:00 – 12:15 |
| 3d | The development of policy measures on medical devices using AI technology in Japan | Fumihito Takanashi, Deputy Director Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (MHLW), Japan | 12:15 – 12:30 |
| 3e | Panel discussion | Panelists | 12:30 - 13:00 |
| Lunch break | | | 13:00 – 14:00 |

| Section 4: Overview of AI standardization activities | | | |
|---|---|--|---------------|
| • State-of-play of existing initiatives | | | |
| 4 | Overview of AI standardization activities. <i>Multiple international standard initiatives regarding AI in healthcare incl. at ISO, IEC and WHO levels.</i> | Pat Baird, Philips *via Webex | 14:00 – 14:30 |
| Section 5: Challenges for Healthcare Professionals and patients | | | |
| <ul style="list-style-type: none"> • Questions of clinical evaluation/evidence/investigation of AI based software • Data quality and availability, protection, interoperability, cybersecurity • Liability • The problem of responsible party determination in the sphere of AI application. Concerns of healthcare professionals as well as software manufacturers | | | |
| 5a | Experience of introducing products based on artificial intelligence in the health care of Yamal | Olga Belorus, Director of Medical Information and Analytical Center, YNAO, Salekhard, Russia | 14:30 – 14:45 |
| 5b | Experience in testing and comparing different solutions based on artificial intelligence for the Moscow health service | Sergey Morozov, Chief Freelance Specialist in Radiation and Instrumental Diagnostics, Director of the Scientific-Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Department, Russia | 14:45 – 15:00 |
| 5c | Preparation and conduct of clinical trials of the support system for making medical decisions based on artificial intelligence. | Denis Gavrilov, Chairman of the Karelian Republican Branch of the Russian Society of Cardiology, Russia | 15:00 – 15:15 |
| 5d | How industry can cope with challenges? | Philippe Lartigue, GE Healthcare | 15:15 - 15:30 |
| 5e | Industry responsibility and liability | Pat Baird, Philips *via Webex | 15:30 – 15:45 |
| 5f | Panel discussion | Panelists | 15:45 – 16:05 |
| Coffee/tea break | | | 16:05 – 16:35 |
| Section 6: Regulatory challenges - what applies to AI? | | | |
| <ul style="list-style-type: none"> • Conformity assessment • Change control • Feasibility of creating AI adaptation rules and algorithm change protocol (ACP) • Cybersecurity | | | |
| 6a | Introduction to review points for decision-making medical device software using deep learning technology | Peng Liang, Deputy director of division I of Center for Medical Device Evaluation (CMDE), National | 16:35 – 16:50 |

| | | | |
|---|---|---|---------------|
| | | Medical Products Administration (NMPA), China* <i>*via Webex</i> | |
| 6b | Regulatory challenges for AI – a European RA perspective | Matthias Neumann, Federal Ministry of Health Germany, EU | 16:50 – 17:05 |
| 6c | Industry overview on regulatory challenges | Naoki Morooka, Shimadzu | 17:05 – 17:20 |
| 6d | Applying Advanced Technology in Clinical Practice: Regulatory Approval Cases of AI Software | Jungin Lee, Lunit | 17:20 – 17:35 |
| 6e | Panel discussion | Panelists | 17:35 – 17:50 |
| Section 7: Concluding Remarks & Next Steps | | | |
| 7 | Conclusions | Moderators | 17:50 – 18:00 |